ALX Oncology, Eli Lilly to Evaluate Gastric Cancer Treatment
10 June 2021 - 9:40PM
Dow Jones News
By Chris Wack
ALX Oncology Holdings Inc. said it has entered into a clinical
trial collaboration and supply agreement with Eli Lilly & Co.
to evaluate the combination of ALX148, a next-generation CD47
blocker, and Cyramza ramucirumab, Lilly's anti-VEGFR2 antibody, for
the treatment of patients with HER2-positive gastric cancer or
gastroesophageal junction cancer.
Under the terms of the agreement, ALX Oncology will conduct a
randomized Phase 2/3 study to evaluate the efficacy of ALX148 in
combination with ramucirumab, trastuzumab, and paclitaxel for the
treatment of patients whose tumors have progressed following
treatment with HER2-targeted therapy and chemotherapy. Lilly will
supply ramucirumab for this trial.
Financial details of the collaboration agreement are
undisclosed.
ALX Oncology owns worldwide commercial rights to ALX148.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 10, 2021 07:35 ET (11:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024
